In addition to targeting Mucin1 overexpressed in breast cancer, pancreatic cancer, B cell lymphoma, and multiple myeloma, DCs can also be engineered to express many other specific monoclonal scFvs against antigens, including alpha-fetoprotein, CA-125, Her-2, mesothelin, prostate stem cell antigen, and Claudin 18.2 on cancer cell surfaces. The gene discussed is MSLN; the disease is B-cell non-Hodgkin lymphoma.